Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients

• Published in: American journal of hypertension Vol. 6; no. 3 Pt 2; p. 86S
• Main Authors: Manolis, A J, Kolovou, G, Handanis, S, Athanasopoulos, G, Antonopoulos, S, Cokkinos, D V
• Format: Journal Article
• Language: English
• Published: United States 01.03.1993
• Subjects: Adult; Echocardiography, Doppler; Female; Heart Ventricles - diagnostic imaging; Humans; Hypertension - complications; Hypertension - drug therapy; Hypertrophy, Left Ventricular - diagnostic imaging; Hypertrophy, Left Ventricular - drug therapy; Hypertrophy, Left Ventricular - etiology; Isradipine - therapeutic use; Male; Middle Aged; Treatment Outcome
• ISSN: 0895-7061
• DOI: 10.1093/ajh/6.3.86S

The regression of left ventricular hypertrophy (LVH) is considered a desirable goal of antihypertensive treatment. Isradipine was used as first-line antihypertensive treatment in 15 patients who had mild-to-moderate hypertension and LVH, and who were studied before and after 6 months of treatment. Left ventricular mass and function were assessed by Doppler echocardiography. Systolic and diastolic blood pressure were reduced from 161 +/- 14 mm Hg and 103 +/- 3 mm Hg to 136 +/- 8 mm Hg and 87 +/- 6 mm Hg, respectively (P < .001). The interventricular septal thickness was reduced by 11.9% (P < .001), posterior wall thickness by 11.1% (P < .001), left ventricular end-diastolic diameter by 2%, and left ventricular mass index by 17% (P < .02). In conclusion, 6 months of antihypertensive treatment of mild-to-moderate hypertension with isradipine achieves a significant regression (17%) of LVH.